Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: Robert C. Petersen who wrote (893)	4/18/1998 4:35:00 PM
From: Rob	Read Replies (2) \| Respond to of 1501

To all: For those who would like a general review of transcription factors with an emphasis on the history and mechanism of NF-kb, as well as insight into another well-capitalized company working on nf-kb inhibition, I recommend requesting the investor packet from Signal Pharmaceuticals (619 558 7500). The NEJM review article mentioning NF-kb ( April '97) was written in part by one of the founding scientists of this company. They will undoubtedly be a top competitor. Rob